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Summary 
Implant-associated infections caused by Candida spp. are difficult to treat due to reduced 
antimicrobial susceptibility in biofilm. Antifungal susceptibility testing is important due to the 
increasing number of prosthetic infections caused by Candida spp. The aim of this thesis was to 
investigate innovative methods using calorimetry for microbial detection and antimicrobial 
susceptibility testing, as well as treatment activity in validated C. albicans foreign-body infection 
animal model (part 1). In addition, new materials with intrinsic antimicrobial activity (bioactive 
glass) were tested (part 2).  
 
The first part of the thesis describes a novel real-time method for evaluation of antifungals against 
yeast, based on measurements of the growth-related heat production by isothermal 
microcalorimetry. Current methods for evaluation of antifungal agents against yeast have several 
limitations, especially when combinations of antifungals are investigated. We therefore evaluated 
the activity of fluconazole, amphotericin B and two echinocandins (caspofungin and anidulafungin) 
against Candida spp. by microcalorimetry. The minimal heat inhibition concentration (MHIC) was 
defined as the lowest concentration inhibiting ≥50% (≥90% for amphotericin B) of the heat 
produced at 24 and 48h for planktonic and biofilm yeast, respectively. Agreement within two-fold 
dilutions between MHIC and MIC was 50% for fluconazole and 100% for caspofungin, 
anidulafungin and amphotericin B. As determined by microcalorimetry, echinocandins (especially 
anidulafungin) were the most active agents against planktonic Candida. Subsequently, 
antimicrobial treatment strategies for infections caused by Candida albicans in-vivo were 
investigated. Since C. albicans had not previously been tested in this animal model, we first 
established an infection profile and investigated the pharmacokinetics of antifungals. In untreated 
animals, planktonic Candida progressively decreased in cage fluid and was cleared in 8% to 24% 
of cage fluids, however, Candida biofilm persisted on all cages, i.e. no spontaneous cure of cage-
associated infections was observed. In accordance with in vitro experiments, echinocandins 
showed the highest activity against planktonic C. albicans. Against C. albicans biofilm, 
caspofungin showed the highest cure rate (25%), whereas cure rates of other antifungals ranged 
between 8% - 17%, demonstrating the difficulty of eradicating Candida biofilms on implants.  
 
The second part of the thesis investigates the activity of bioactive glass (BAG) S53P4 (volumes 1 
g and 2 g and sizes 0.5-0.8 mm and <45 µm) against Staphylococcus aureus, S. epidermidis, 
Escherichia coli, Enterococcus faecalis et Candida albicans by microcalorimetry. BAG is a 
surface-reactive glass-ceramic biomaterial which is used as implant material to repair and replace 
diseased or damaged bones. Besides binding chemically to the bone and being osteoconductive, 
this material has the property to inhibit the biofilm formation. BAG showed good activity against 
tested mircoorganisms, except for E. faecalis with granula 0.5-0.8 mm.  
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Résumé 
Les infections associées aux implants causées par Candida spp. sont difficiles à traiter à cause de 
la faible susceptibilité du biofilm aux antifongiques. Le test de susceptibilité aux antifongiques est  
important vu  l’augmentation des infections de prothèses dûes à Candida spp. Le but de cette thèse 
est d’étudier des nouvelles méthodes de détection des microorganismes par calorimétrie et de tester 
la susceptibilité ainsi que l’activité des antifongiques dans un modèle animal (partie 1). De plus, 
des nouveaux matériaux avec une activité antimicrobienne intrinsèque (bioactive glass) ont été 
testés (partie 2).  
 
La première partie de la thèse décrit une nouvelle méthode d’évaluation de l’effet des 
antifongiques en temps réel en se basant sur la chaleur produite lors de la croissance mesurée par 
microcalorimètre isothermique. Les méthodes actuelles visant à évaluer l’effet des antifongiques 
sont limitées, surtout lorsqu’il s’agit d’évaluer l’effet des combinaisons d’antifongiques. Nous 
avons évalué l’activité du fluconazole, de l’amphotericin B et des echinocandines (caspofungine et 
anidulafungine), sur différentes souches de Candida spp. La concentration minimale d’inhibition 
de chaleur (CMIC) a été définie comme étant la plus petite concentration inhibant  ≥50% (≥90% 
pour l’amphotericine B) de la chaleur produite à 24h et 48h pour la croissance planctonique et du 
biofilm. La concordance entre CMIC et la concentration minimale d’inhibition (CMI), avec 2 
dilutions de marge, était de 50% pour fluconazole et 100% pour les echinocandines et 
l’amphotericin B. Comme déterminé par microcalorimétrie, les echinocandines (surtout 
l’anidulafungine) ont montré une meilleure activité contre la croissance planctonique de Candida. 
Nous avons ensuite étudié les traitements antimicrobiens contre C. albicans in vivo. Étant donné 
l’absence d’études avec ce modèle animal avec C. albicans, nous avons d’abord établi un profil 
d’infection et étudié la pharmacocinétique des antifongiques. Chez les animaux non traités, 
Candida planctonique a montré une décroissance progressive dans le fluide des cages, tout en 
restant présent sous forme de biofilm. Pas de cure spontanée des cages infectées a été observée. En 
accord avec les expériences in vitro, les echinocandines ont montré une meilleure activité contre 
C. albicans planctonique. Contre le biofilm la caspofongine montre le plus haut taux de guérison 
(25%), contrairement aux autres antifongiques où le taux de guérison allait de 8% à 17%, 
démontrant ainsi la difficulté rencontrée dans l’éradication du biofilm à C. albicans.  
 
La deuxième partie étudie l’activité du bioactive glass (BAG) S53P4 (volumes 1 and 2 g et 
diamètres de 0.5-0.8 mm et <45 µm) contre Staphylococcus aureus, S. epidermidis, Escherichia 
coli, Enterococcus faecalis et C. albicans. BAG est un biomatériel en vitre-céramique à surface 
réactive utilisé en tant qu’implant pour réparer et remplacer les os endommagés ou fracturés. En 
plus d’avoir la capacité de se lier chimiquement à l’os et être ostéoconductif, ce matériel a la 
caractéristique d’inhiber la formation du biofilm. BAG a montré une bonne activité contre les 
microorganismes testés à l’exception de E. faecalis avec les granules de 0.5-0.8 mm de diamètre. 
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Chapter1. General introduction 
Fungal infection 
Fungal infections are on the rise as advances in modern medicine prolong the lives of severely ill 
patients. Candida spp., Aspergillus spp. and Cryptococcus neoformans are the most common 
agents of fungal infections and the mortality rate often remains higher than 50% (1). Candida is 
considered as being the most important cause of opportunistic mycoses, and is the fourth most 
common cause of nosocomial infections (2, 3).  
Candida is a commensal type of yeast well tolerated by healthy humans. It is found on the oral 
mucosa, on the skin, in the gastrointestinal tract and in the vaginal flora. However, it can become 
pathogenic and induce mycosis in diabetic people or whenever the immunosystem is deficient (e.g. 
in HIV infected patients).  
Candida is a polymorphic species, meaning that it can grow either as budding yeast or as 
filamentous cells (pseudohyphal or hyphal form), and can switch from one form to the other 
depending on environmental conditions such as temperature and pH. The primary mode of 
reproduction in C. albicans is by the budding of yeast cells. Mother cells give rise to daughter cells, 
which are released to repeat the budding cycle. 
In the past decades various risk factors for fungal infections have emerged, including the use of 
indwelling devices, transplantation procedures, immunosuppression,  prolonged intensive care unit 
stays and use of broad-range antibiotics suppressing normal bacterial flora, increasing the 
prevalence of fungal disease (4, 5). More than 90% of invasive infections due to Candida spp. are 
attributed to five species, C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei, and 
the list of species isolated from clinical specimens continues to grow each year (2, 6).  
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The evolving epidemiology of non-C. albicans species may reflects the increased use of antifungals 
for prophylaxis and the introduction of new antifungal agents in clinical use. C. glabrata, for 
example, may be less susceptible to fluconazole, the most inexpensive and readily available 
antifungal agent used to treat candidemia. Similarly to bacteria, fungi can attach to the implant 
surface and form biofilm, causing persistent and relapsing infections (7, 8). 
 
Fungal biofilm formation on medical devices 
In contrast to the vast literature describing bacterial biofilms, less attention has been given to 
medically important fungal biofilms. Among implant-associated biofilm infections, Candida is 
implicated in about 1-5%. These infections are difficult to treat, and usually requires removal of 
the implant and prolonged antifungal treatment (9-12). 
C. albicans biofilm formation proceeds mainly through three developmental phases: the early 
phase, the intermediate phase and the maturation phase. The early phase take place between 0 and 
~11h and it involves the adhesion of fungal cells to the substrate. The intermediate phase, between 
~12 and 30h, imply the coaggregation and the proliferation of blastospores creating communities 
and producing an extracellular matrix (ECM) rich in carbohydrates. The maturation phase, between 
~31and 72h, includes the formation of a thick ECM in which the fungal cells are completely 
embedded (13). 
In a study performed by Depprich et a.l comparing the prevalence of microorganisms on different 
materials C. albicans was demonstrated to be able to form biofilm on silicone but not on titanium. 
This biofilm formation was mainly due to the light roughness of the titanium surface (14). This 
study also revealed the formation of biofilm on the silicone interior, thus demonstrating the 
importance of the porosity of the biomaterial. Characteristics such as pores, fissures and structural 
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defects increase the surface area and provide an accommodation for microorganisms, supporting 
biofilm formation (8, 15). 
 
Antifungals 
Fungi are eukaryotic organism and, as being evolutionarily close to humans, there are limited 
numbers of targets which can be exploited for antifungal drug development. The ﬁrst agent with 
antifungal activity, griseofulvin, was isolated in 1939, whereas the ﬁrst azole and polyene 
antifungal agents were reported in 1944 and 1949, respectively. Although their discovery in the 
1940-50, it was only in the sixties that oral griseofulvin became available for clinical use (16). 
Serious fungal infections increased during the 1980s and 1990s with the increased use of 
immunosuppressive agents and due to the increased number of immunocompromised or severely 
ill individuals. The most common reason to immunosupression was the spread of human 
immunodeﬁciency virus (HIV) infection, followed by organ transplants, chemotherapy, and 
improved life-saving medical techniques necessitating indwelling devices (17). 
The consequent growing need for antifungal agents brought new drugs to the market and led during 
the1990s to new lipid formulations of amphotericin B with improved safety proﬁles (18). In 
addition, new classes of antifungal agents such as the echinocandins were studied (18, 19).  
Antifungals can be classified into different classes according to their mode of action. These classes 
comprise polyenes, acting on membrane function, allylamines and azoles, targeting specifically the 
biosynthesis of the major component of the fungal cell membrane, ergosterol (equivalent to 
cholesterol in mammalian cells) (Figure 1). Other classes of antifungals act on the biosynthesis of 
cell wall, such as the echinocandins or pradimicin, on the biosynthesis of nucleic acids, such as 5-
fluorocytosine, or they inhibits the activity of mitochondrial function, such as the histatins (16, 17, 
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20). Nowadays, the main classes of antifungals therapeutically used are polyenes, azoles and 
echinocandins. 
 
Figure1. Overview of the mechanisms of action of the antifungal classes, azoles (A), polyenes (B), flucytosine (C) and 
the echinocandins (D), used for treatment of Candida infections. From (20) 
 
Polyenes 
Since the discovery of the polyenes and their introduction in the 1950-60s, amphotericin B remains 
the “gold standard” of antifungal therapy. Amphotericin B binds ergosterol, the principal sterol in 
the fungal membrane, creating pores that compromise membrane integrity causing leakage of 
cellular components and death (21). 
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Nevertheless, the efficacy of polyenes is limited by their intrinsic toxicity. Therefore, lipid 
formulations of amphotericin B have subsequently been developed. 
Azoles 
Azoles, such as fluconazole, were developed in the 1980s. Azoles are synthetic fungistatic drugs, 
inhibiting the biosynthesis of ergosterol. They target the cytochrome P 450 14-α-lanosterol 
demethylase (encoded by ERG11 or CYP51) thus inhibiting its enzymatic activity. This enzyme 
also plays an important role in the cholesterol synthesis in mammals. Another target of azoles 
recently described is the enzyme Δ22-desaturase, which is a cytochrome P-450 involved in the last 
step of the biosynthesis of ergosterol. Azoles cause depletion of ergosterol, leading to accumulation 
of 14a- methylated sterols into the fungal cell, as well as the disruption of the structure of the 
membrane and several of its functions, such as nutrient transport and chitin synthesis. These 
antifungals are the most important agents used therapeutically in clinic due to their moderate toxic 
effects (16). Although the improved safety profile compared to amphotericin B, the major problem 
with azoles is the emergence of resistance given by the development of point mutation on the target 
enzyme as well as the over-expression of genes encoding efflux pumps (22-25). 
 
Resistance to azoles  
The appearance of resistance to antifungal drugs led to failure of treatment and persistence of fungal 
infection despite an appropriate antifungal drug therapy. While resistance to polyenes, such 
amphotericin B, has been rarely reported in yeast, resistance to azoles has been extensively reported 
since 1980. The fungistatic effect of azoles and their repeated use led to the increased appearance 
of resistance to these agents. As a consequence of the increasing number of HIV patients infected 
by Candida, the use of the corresponding agent has also been more frequent. The resistance to 
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azoles has been explained by three major reported mechanisms: 1. drug efflux transporters, 2. 
ergosterol biosynthesis pathway modifications and 3.the mediation by Erg11p gene.  
1. A large number of Candida clinical azole-resistance strains, especially C. albicans and C. 
glabrata, showed increased azole efflux which has been correlated to the upregulation of multidrug 
efflux transporter genes from two distinct families In the ATP binding cassette (ABC) transporters 
family (CDR1, CDR2 and CSNQ2), ATP is used as driving force for drug efflux, and in the Major 
Facilitator Superfamily (MFS), a proton gradient is used for drug efflux. Deletion of CDR1 in C. 
albicans leads to a hypersusceptibility to azoles and an accumulation of fluconazole (26, 27). 
2. Some azole-resistant strains showed to have specific alterations in the ergosterol biosynthesis 
pathway, often resulting in the absence of ergosterol. Some C. albicans resistant strains have been 
found to accumulate 14α-methyl-3,6-diol, which indicates a defect in the enzyme sterol Δ5,6 
desaturase encoded by the gene ERG3 (28). 
3. The final major mechanism is linked to the overproduction or Erg11p. Upregulation of ERG11 
plays a moderate role in C. albicans azole resistance, however, in clinical azole-resistant isolates 
three specific regions of Erg11p have been reported with amino acid substitutions close to the 
cytochrome P-450 active site (29). 
 
Echinocandins 
Echinocandins are the last new class of antifungal introduced to the market (i.e. caspofungin, 
micafungin and anidulafungin). This antifungal class has the particularity to be the first that acts 
against a specific component of the fungal organisms not present in mammalian cells, the cell wall, 
thus avoiding direct human cell toxicity (30). The echinocandins exhibit fungicidal activity against 
Candida spp., including azole-resistant species, but fungistatic activity against Aspergillus spp. 
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The echinocandins are non-competitive inhibitors of 1,3-β-D-glucan synthase (and, to a lesser 
extent, 1,6-β-D-glucan synthase), an enzyme complex within the fungal cell wall comprised of at 
least two subunits: Fks1p (encoded by the genes FKS1, FKS2 and FKS3) and Rho1p. FKS1 
transcription is linked to cell wall remodelling in fungi and FKS2 transcription is calcineurin 
dependent. Rho1p is a key regulatory protein and because of his interaction with multiple proteins, 
Rho1p is thought to be a key switch driving or arresting the synthesis of 1,3-D-glucan. Specifically, 
the echinocandins target the FKS1 gene product with Fks1p being the active site of the enzyme, 
although the precise echinocandin binding site remains unresolved. Fks1p inhibition is 
concentration dependent. Since 1,3-β-D-glucan is an integral component of the fungal cell wall, 
changes in its characteristics compromise osmotic stability resulting in cell lysis (31-33).  
 
Clinical relevance of antifungal susceptibility testing 
The main objective of all in vitro antimicrobial susceptibility testing, antibacterial, antiviral as well 
as antifungals, is to predict the outcome of the clinical administration of a tested agent on the 
organism causing the infection. As antibacterial testing, antifungal susceptibility testing aim to 
provide 1) an estimation of the activity of single or combined antimicrobial agents against the 
pathogen of interest; 2) a good correlation with the in vivo activity; 3) to detect the development of 
resistance; and 4) to test new antimicrobials and asses their spectrum of activity. 
The currently available international standard methods for susceptibility determination of yeast to 
antifungals agents have been developed by the Clinical Laboratory Standards Institute (CLSI) (34) 
and by the Antifungal Susceptibility Testing Subcommittee of EUCAST (EUCAST-AFST) (35). 
A microbroth dilution assay is recommended by both guidelines for the determination of the 
minimal inhibitory concentration (MIC). Furthermore, the two guidelines differ in the inoculum 
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size (0.5-2.5 x 103 vs 0.5-2.5 x 105 CFU/ml), the test culture media used (RPMI 1640 with 0.2% vs 
2% of glucose), the microtitration plates (U-shaped vs flat-bottom wells) and in the method of 
reading (visually versus photometrically). Moreover, the MIC is defined as the lowest 
concentration inhibiting the growth with amphotericin B by 100% vs 90%, with azoles and 
echinocandins by 50% for both (36). 
Several other commercial test assays have been developed to facilitate the antifungal susceptibility 
testing. E-test and disk diffusion testing have been developed for yeast and moulds producing easy-
to-read and sharp zones of inhibition (37, 38). Sensititre Yeast One is a colorimetric antifungal 
panel including Alamar-blue that converts into pink in the presence of growth and it is easy to 
interpret. Compared to the reference method (CLSI), Sensititre Yeast One has showed good 
agreement (39). 
Mostly, free-living cells (planktonic) in pure culture are used to assess the MIC. However, different 
factors have been identified that can affect the results of in vitro tests with antifungal agents. For 
example, the method used for the endpoint determination is complicated for a number of 
antifungals, especially the azoles, because of the often reported trailing phenomenon. In this case 
the fungi will initially growth even with high concentrations of the antifungal agent. Furthermore, 
planktonic results are rarely useful when biofilm is present.  Regarding the evaluation of biofilm 
susceptibility a colorimetric cell proliferation assay (XTT) using reduction of tetrazolium salt has 
been established for quantitative analysis of biofilm growth (40), however, the validity and 
reproducibility of this method has been questioned (40, 41). Therefore, other quantitative methods, 
such as the ATP bioluminescence assay or the incorporation of an isotope have been investigated 
(36), but none is universally accepted as the reference method for evaluating susceptibility of 
Candida biofilms. Furthermore, most of the models for the formation of microbial biofilm, are 
cumbersome, time-consuming, labor-intensive and need experienced personnel for interpretation. 
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These models include the use of catheter disks, plastic slides, cylindrical cellulose filters, modified 
devices, the Calgary biofilm device, etc. under static or dynamic conditions (42-46).  
An early detection of infections caused by antifungal specific resistant pathogens optimises the 
choice of treatment and the patient outcome. However, it is difficult to correlate in vitro 
susceptibility testing results with the human treatment outcome of an infection. The in vitro test 
does not take into account the dynamics of an in vivo infection. Factors such as the host immune 
response, drug pharmacokinetics and pharmacodynamics, drug interactions as well as the 
interaction with the host proteins are neglected. All this parameters can also influence the outcome 
of the treatment of a specific infection (47, 48). The accuracy between the in vitro and in vivo data 
has been summarized as the “90-60 rule”: “infections due to isolates that are susceptible to the 
agent being given respond to therapy approximately 90% of the time, whereas infections due to 
isolates that are resistant to the agent being given respond approximately 60% of the time” (47). 
Great efforts concerning standardisation have been made by both organisations, the CLSI and the 
EUCAST, establishing clinical breakpoints for in vitro antimicrobial susceptibility testing 
indicating the likely response to a given antimicrobial agent using the approved dosing regimen for 
that agent. Epidemiological cutoff values have also been established as a sensitive marker for the 
emergence of decreased susceptibility to the given agent discriminating non-wild type strains (with 
mutational or acquired resistance mechanisms) from wild-type. Nevertheless, given the differences 
between the two methods, breakpoints suggested by CLSI cannot be extrapolated to the EUCAST 
method and vice versa. Antifungal susceptibility testing can aid in the selection and optimization 
of antifungal treatment and due to the low number of antifungals on the market, having a good and 
rapid antifungal susceptibility testing is extremely important for surveillance of the emergence of 
resistance. 
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Calorimetry in microbiology 
Isothermal microcalorimetry is a highly sensitive non-invasive and non-destructive technique, 
measuring heat produced by microorganisms in the range of microwatt. The release of heat by 
microorganisms is proportional to their metabolism and growth rate and can be recorder in real 
time and plotted as heat flow (Watt) versus time. Measurements are performed at constant pressure 
and temperature as evocated by the name “isothermal”. The slope of the heat flow curve at each 
time point depends on the replication rate of the cells, while the area under the heat flow curve 
correspond to the total heat (Joule), which is proportional to the final number of cells (Figure 2) 
(49). 
 
Figure 2. Relation between the microcalorimetric measurements and their biological equivalents. The heat 
flow represents the activity (growth rate) of a microbial culture. The area under the heat-flow curve gives the total 
amount of heat produced, representing the final product resulting from microbial activity (total number of cell). 
Adapted from (49). 
 
Due to its high sensitivity and precision, the multi-channel batch calorimeters of heat-conduction 
type are the mostly commonly reported for clinical microbiology. The Thermal Activity Monitor 
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(TAM 48, TA Instruments, New Castle, DE, USA), shown in figure 3 is an example of a batch 
isothermal thermophile calorimeter allowing parallel measurements of different samples in 48 
independent channels with a detection sensitivity on the order of 0.2 µW. Considering that a single 
bacteria cell produces ~2 pW (1 pW for fungi) when active, only 105 bacteria are required to 
produce a detectable signal. A glass ampoule can contain 1-4 mL of liquid enabling the detectable 
concentration of active microorganisms between 2.5 x 104 and 1.0 x 105 bacteria/ml. This cell 
concentration would not be detectable using a spectrophotometer (i.e. measuring the turbidity at 
600nm) (50, 51). 
The calorimeter provides a continuous real-time electronic signal proportional to the temperature 
differential measure between the sample (microorganisms culture) and the heat sink reference, 
generally made of aluminium, within a well-defined temperature (see figure 3). 
 
Figure3.  
A. The isothermal 
micrcocalorimeter TAM 48 (TA 
Instruments) with 48 
independent channels.  
 
B. A schematic picture of a 
calorimetric channel including 
the heat sink (inert reference) and 
the sample (a 4 ml glass ampoule 
hermetically closed). The 
thermopile measures the 
difference in heat between the 
sample and the reference under a 
constant temperature. 
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The heat between the sample and the heat sink is transferred through a thermopile consisting of 
coupled Peltier elements. The Peltiers elements act as thermoelectric generators and convert the 
temperature difference between the sample and the reference into a voltage signal that is 
proportional to the heat. 
To increase the sensitivity and accuracy, most of the current isothermal microcalorimeters are “twin 
instruments”. The reaction vessel, including the sample and the heat sink, is inserted into a precise 
liquid thermostat (water or oil), adjustable between 15–150°C, ensuring a temperature stability of 
10-5 °C. The thermostat temperature in a microbiological setting is normally set at 37°C. 
Calorimetry samples are easy to prepare and they do not need specific preparation.  Samples are 
placed in sealed glass ampoules and inserted in one of the measuring channels. Heat production is 
monitored and recorded as long as there is a heat flow signal (from hours to days). After the heat 
measurement, samples can also be used for further analysis of interest. Nevertheless, isothermal 
microcalorimetry has a major drawback which is the non-specificity of the heat-flow signal related 
to the sum of all chemical and physical processes taking place into the ampoule. Simultaneous 
exothermic and endothermic processes are unspecifically recorded. Furthermore, since the samples 
are placed in sealed ampoules, chemical factors such as oxygen depletion and accumulation of 
metabolic waste products have to be take into account during the interpretation of the results (49).  
The potential of isothermal microcalorimetry is in the fast detection of microbial infections or 
contamination, which is of critical importance for the clinical diagnosis and administration of the 
appropriate treatment. Several studies have shown the potential of the isothermal microcalorimetry 
to detect growth of different pathogens within a few hours, as, for example, the contamination of 
donated blood platelets with Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus 
sanguinis, Escherichia coli, Propionibacterium acnes and Candida albicans (52), the urinary tract 
 
 
20 
infections (53) or mycobacterial (54). Since the microcalorimeter does not differentiate between 
growths of different microorganism, the use of selective growth media may allow the recovery and 
detection of specific microbes when present in the specimens.  
It is also possible to determine the minimal inhibitory concentration (MIC) for different 
antimicrobial agents and microorganisms within hours (55). In the presence of an active 
antimicrobial agent at concentration above the MIC, susceptible microorganism will be inhibited 
leading to absence of heat production. Contrarily, resistant microorganism will not be inhibited and 
heat will be produced. This will allow rapid detection of resistant microorganisms. The use of 
isothermal microcalorimetry for the differentiation of methicillin-susceptible from methicillin-
resistant Staphylococcus aureus within 5 h was reported (56), as well as determination of 
antimicrobial susceptibility of Escherichia Coli, S. aureus, Aspergillus spp. and non-Aspergillus 
molds (55, 57-59). In addition, isothermal miccrocalorimetry has proven to be an effective tool in 
detecting slow-growing bacteria, such as Mycobacterium tuberculosis which could be detected 
within hours using microcalorimetry (54). This is much faster than traditional methods that may 
need up to 60 days to detect growth of slow-growing mycobacteria. Anti-parasitic drugs have also 
being studied with calorimetry against Trypanosoma brucei rhodesiense and Plasmodium 
falciparum (60) as well as Schistosoma mansoni (61). 
One of the main advantages of microcalorimetry is that it can accommodate any type of sample. 
For biomedical material or biofilm studies this means that a solid sample, with or without 
previously formed biofilm, can be introduced into the microcalorimeter ampoule. This allows, on 
one side, to monitor the effect of additives used to improve strength or other properties of bone 
cements. On the other side, in presence of microorganisms, it allows to study the biofilm adherence 
on a determined substrate (15).  
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Although several studies have been performed to demonstrate the potential and benefits for clinical 
applications, calorimetry methods are not yet fully integrated into the microbiologic routine 
procedures. The current cost of multichannel calorimeters is, for instance, too high for cost-efficient 
clinical laboratory tests. However, the non-invasive and non-destructive character of calorimetry, 
as well as the simplicity in sample preparation, qualifies the isothermal multichannel calorimetry 
as a valuable tool for the evaluation of antimicrobial inhibitory profiles, including the evaluation 
of biofilm growth on surfaces (50). 
 
Prosthetic joint infections 
The increasing use of implanted devices consequently leads to an increase of implant-associated 
infections (62). The risk of infectious complications after joint replacement is estimated to be 1-
2%. In patients with primary joint replacement, the infection rate during the first 2 years is less 
than 1% in hip and shoulder prosthesis, less than 2% in knee prosthesis and less than 9% in elbow 
prosthesis. Prosthetic joint infections (PJIs) are difficult to treat and are associated with morbidity 
and elevated health care cost (2, 3). Implant-associated infections are typically caused by 
microorganisms growing in biofilms structures. Eradication of the embedded biofilm requires 
intensive antimicrobial therapy. Staphylococci are the most frequent infective agents, followed by 
streptococci, enterococci, gram-negative bacilli and Propionibacterium acnes. However, less 
prevalent organisms, such as fungi, are currently considered a difficult to treat organism, and the 
optimal eradication treatment is not yet defined. Prosthetic infections caused by fungal agents are 
considered to be rare, representing 1% of orthopaedic infections, and the optimal antifungal 
treatment against C. albicans biofilm has not been defined. In the biofilm form, fungi are up to 
1000-fold more resistant to antimicrobials than in their planktonic form (63). The most frequent 
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fungal agent is C. albicans, followed by C. parapsilosis and C. glabrata. Although fungal 
prosthetic joint infections are rare, they represent a diagnostic and therapeutic challenge.  
In contrast to bacterial infections, which can be locally treated by insertion of an antibiotic-loaded 
spacer, data on efficacy of local antifungal therapy is missing. No clear guidelines exist for the 
surgical management of fungal periprosthetic infections (64). Most patients with chronic infection 
following joint replacement require removal of the device and the standard treatment is a 2 stage-
revision with the use of a temporary spacer impregnated with antibiotics and antifungals allowing 
elution of the drugs directly into the infected surrounding tissue and maintaining the patient’s 
mobility between stages (65). Amphotericin B and fluconazole are the drug of choice for systemic 
treatments, nevertheless, in vitro studies of amphotericin B and fluconazole loaded cement have 
shown only poor elution characteristics for both agents (66, 67). Only a single in vivo study showed 
the efficacy of fluconazole impregnated cement beads in 2 cases in the treatment of periprosthetic 
hip infections (68). 
The exact mechanism of Candida prosthetic joint infection is not elucidated. As for bacterial 
prosthetic infections, 3 possible modes of infections have been described (69):  
1) The haematogenous route is the most frequent mode of infection by Candida. In this case the 
infection originates from microbes coming from a distant infection focus, such as from cutaneous 
infections, soft tissues infections, oral cavity, or infections of the urogenital or the respiratory tract, 
or even from infected catheters. Since the manifestations of the symptoms of such infections occur 
24 months after surgery, they are classified as “late infection”. Late infections are mainly caused 
by highly virulent microorganisms and present all symptoms of acute infections (70, 71). 
2) Direct inoculation after prosthesis implantation into a joint previously infected, or inoculation 
from the skin microflora at the time of implantation (perioperative).  
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3) Extension into the synovial space from adjacent infected tissues. 
The two last modes of infection constitute the most common cause of implant infection. The delay 
of the first symptoms occurs, in those cases, either within 3 months or between 3 and 24 months 
after surgery and such infections have been classified as “early” and “delayed” prosthetic infection 
respectively. In early prosthesis infections the microorganisms involved are generally highly 
virulent pathogens such as S. aureus and gram-negative bacilli. In the delayed infection, low 
virulent pathogens such as coagulase-negative staphylococci, including S. epidermidis or 
Propionibacterium acnes are implied. In this case the infection usually becomes symptomatic later 
than 3months after surgery (11, 72-74). 
The main problem with implants is that foreign surfaces represent good substrates for microbial 
adherence and biofilm formation. Elek and Conen showed that in the vicinity of foreign material 
100 colony forming unit (CFU) of S. aureus was sufficient to induce an abscess, which is more 
than 100’000-fold lower than in the absence of a foreign device (75). This observations were 
confirmed by Zimmerli et al. in an animal model of foreign body-associated infection, where 100 
CFU were sufficient to infect 95% of the subcutaneous cages (simulating the implants), whereas 
>107 CFU of S. aureus could not produce any abscess in the absence of a foreign-body device (76, 
77). 
 
Animal model of implant-associated infections 
The key advantage of studying biofilm infections using animal models is the presence of a 
physiological environment. Moreover, in vivo studies are particularly important for evaluation of 
the pharmacokinetics and pharmacodynamics of antimicrobial agents since different factors may 
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influence the interaction between the drug and the microorganism or its efficacy (77). Depending 
on the problem under study, different models of foreign-body infection have been used to solve the 
multiples problems associated with the foreign-body device (58, 78-81). Currently, animal models 
have been described based on catheter-associated urinary tract infections or infections of different 
materials implanted subcutaneously or intraperitoneally on mice, rats or guinea pigs. Nevertheless, 
the major disadvantage is linked to the high costs of the experimental animal and the laborious and 
sophisticated surgical technique required. An animal model for the study of the pathogenesis, the 
management and prevention of a device-related infection needs to reproduce the same 
characteristics of the human infection, such as not showing spontaneous healing, if it intends to be 
clinically relevant. In the case of a human device-associated infection, the model which best 
reproduces the clinical characteristics is the tissue-cage infection model using guinea pig developed 
by Zimmerli et al. (76, 82, 83). The guinea-pig tissue-cage infection model has the characteristics 
of being very similar to human device-associated infection. 
Foreign-body infections are convenient to study by inserting an implant which is consequently 
infected (locally or hematogenously). After a preferred time of infection, the device can be 
explanted and the presence of biofilm evaluated. Different methods are used to evaluate the 
presence of biofilm, such as examination by confocal scanning microscopy of microorganism cells 
and the extracellular matrix stained with specific dyes, or examination by scanning electron 
microscopy. 
 
The tissue cage infection model 
Male albino guinea pigs (Charles River, Sulzfeld, Germany) were kept in the Animal Facility of 
the University of Lausanne, Switzerland. The experiments were performed according to the 
regulations of Swiss veterinary law. Guinea pigs were weighted every week to ensure their well-
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being. Short-term studies (7-day infection) were performed in a foreign-body cage model with 
guinea pigs to evaluate the infection profile. Animals were anesthetized with a subcutaneous 
injection of ketamine and xylazine. Four sterile polytetrafluorethylene (Teflon) cages with 130 
regularly spaced perforations of 1 mm diameter (Angst-Pfister AG, Zürich, Switzerland) were 
subcutaneously implanted in flanks of the guinea pigs (450 – 550 g) under aseptic conditions, 
allowing accumulation of inflammatory fluid, Candida  inoculation and pharmacokinetic studies. 
After complete wound healing (approximately two weeks after implantation), sterility of the cages 
was confirmed by culturing aspirated cage fluid on blood agar plates and cages were infected by 
injection of a well-defined Candida inoculum. In general, the minimal infective dose needed to 
achieve a stable infection of the cage in guinea pigs is in the range of 102-103 CFU for staphylococci 
and of 104-106 with C. albicans. In rat or mouse models, the minimal infective dose is higher and 
immunosuppression may be needed to prevent spontaneous healing of the infection (84, 85). 
Contaminated cages were excluded from further studies. Sterile cages were used for the 
pharmacokinetic studies by aspirating the tissue-cage fluid after intraperitoneal injection of 
different doses of the drug. Fungal inoculation was performed only in initially sterile cages.  
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For evaluation of the treatment efficacy the tissue-cages are explanted after the end of therapy 
(Figure 4, F) and the cure rate is determined by dividing the number of culture-negative cages by 
the total number of cages in the treatment group. Additionally, the antifungal activity against 
planktonic Candida present in the fluid within the cage can be evaluated by aspirating cage fluid 
before, during and after treatment. 
Different treatment regimens for biofilm infections have been evaluated using tissue-cage infection 
models. When antibiotic are used, guinea pigs are limited by their intolerance to β-lactam and 
clindamycin, which both cause lethal diarrhea. Furthermore, guinea pigs only support short-term 
therapy up to 4 days. Rats are more suited for studying chronic infections and long-term therapy, 
but the infective dose needs to be increased to avoid spontaneous healing (85). 
  
Figure 4. Guinea-pig foreign-body 
implantation and explantation. 
A. Dunkin-Hartley Guinea pig.  
B. Tissue-cage (Teflon cylinders). 
C. Ventral position of the guinea pig 
before implantation. 
D. Subcutaneous insertion of the 
cages. 
E. Closing wound. 
F. Explantation of cages at the end 
of the experiment 
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Chapter2. AIM OF THE STUDY 
 
In this study, we investigated the potential of isothermal microcalorimetry for determination of 
planktonic and biofilm susceptibility testing of the most medically important Candida species. The 
microcalorimetry results were compared with conventional microbroth dilution testing and the 
XTT testing. A rapid and accurate reproducible susceptibility testing method may help guiding the 
choice of an optimal antifungal treatment improving the clinical outcome. Based on in vitro results 
the activity of the same antifungals was tested in vivo on planktonic and biofilm C. albicans in a 
foreign-body infection model using guinea pigs.  
 
The aim of the first part (chapter 3) was to investigate the activity of fluconazole, caspofungin, 
anidulafungin and amphotericin B against planktonic and biofilm Candida spp in vitro. 
The aim of the second part (chapter 4) was to investigate the same antifungals in vivo.  
First, we established an infection profile for different inocula of C. albicans. Second, we studied 
the pharmacokinetics and the pharmacodynamics of different antifungals and third, we investigated 
the activity of antifungals against planktonic and adherent C. albicans in vivo. To our knowledge, 
this is the first description of C. albicans infection and treatment in this model. 
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ABSTRACT 
The optimal treatment against Candida biofilms is not defined. We investigated the antifungal 
activity against planktonic and biofilm C. albicans in a foreign-body infection model. Teflon cages 
were subcutaneously implanted in guinea pigs, infected with C. albicans (ATCC 90028). Animals 
were treated intraperitoneally 12 h after infection for 4 days once daily with saline, fluconazole (16 
mg/kg), amphotericin B (2.5 mg/kg), caspofungin (2.5 mg/kg) or anidulafungin (20 mg/kg). Cage 
fluid was aspirated and planktonic Candida was quantified before, during and after treatment and 
the clearance rate from cage fluid was determined. Cages were removed and cultured to 
determine the biofilm cure rate. In untreated animals, planktonic Candida was cleared from cage 
fluid in 25% (infected with 4.5 x 103 CFU/cage), 8% (infected with 4.8 x 104 CFU/cage) and 0% 
(infected with 6.2 x 105 CFU/cage). Candida biofilm persisted on all explanted cages. Compared 
to untreated controls, fluconazole and amphotericin B did not reduce the number of planktonic C. 
albicans in cage fluid during and after treatment, whereas caspofungin reduced it to 0.22 and 0.0 
CFU/ml, respectively, and anidulafungin to 0.11 and 0.13 CFU/ml, respectively. Fluconazole cured 
2/12 cages (17%), amphotericin B and anidulafungin each 1/12 cages (8%) and caspofungin 3/12 
cages (25%). In summary, echinocandins showed superior activity against planktonic C. albicans 
than amphotericin B and fluconazole. Caspofungin showed the highest cure rate of C. albicans 
biofilm. However, no antifungal exceeded 25% cure rate, demonstrating the difficulty of eradicating 
Candida biofilms from implants. 
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INTRODUCTION 
Candida spp. is rarely causing prosthetic joint infections (PJI), representing about 1-3% of all 
infections, but are difficult to treat and are associated with high morbidity and healthcare cost (1, 
2). Usually a two-step exchange of the prosthesis with a long interval is applied since Candida is 
considered a difficult-to-treat microorganism in implant-associated infection. Little is known about 
the optimal antifungal treatment of Candida PJI. In vitro experiments suggest that microorganisms 
are considerably more resistant to antifungals than their planktonic counterparts (3). In a recent in 
vitro study, fluconazole activity against biofilm Candida was reduced by >1000-fold compared to 
planktonic counterparts, whereas echinocandins and amphotericin B mainly preserved their 
activity (Maiolo EM, Furustrand Tafin U, Borens O, Trampuz A, manuscript in revision AAC01815-
13).  
By using an established animal model of foreign-body infection, the pharmacokinetic and 
pharmacodynamic parameters can be studied in a physiological environment, including the 
interaction between the drug and the microorganism at the site of infection (4). In previous studies, 
antifungals were evaluated in animal models with different materials implanted subcutaneously or 
intraperitoneally in mice, rats or guinea pigs (5-11).  
In this study we investigated the activity of antifungal agents (fluconazole, amphotericin B, 
caspofungin and anidulafungin) against planktonic and biofilm C. albicans in a guinea pig foreign-
body infection model. The tissue cage infection model has been validated for testing the activity 
of antimicrobial agents against implant-associated infections in preclinical studies (12-15). To our 
knowledge, this is the first evaluation of antifungal treatment against C. albicans foreign-body 
infection in this model. 
(Part of the results of this study was presented at the 23rd European Congress of Clinical 
Microbiology and Infectious Diseases, Berlin, Germany, 27 to 30 April 2013 [E. Maiolo, U. 
Furustrand Tafin, A. Trampuz, abstr. P-1097] and at the 32nd meeting of the European Bone and 
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Joint Infection Society, Prague, Czech Republic, 12 to 14 September 2013 [E. Maiolo, U. 
Furustrand Tafin, O. Borens, A. Trampuz, oral presentation]. 
 
MATERIALS AND METHODS 
Study organism. C. albicans (ATCC 90028) was used for in vivo antifungal testing. The strain 
was stored at -80°C by use of a cryovial bead preservation system (Roth, Karlsruhe, Germany) at 
-80°C. C. albicans was cultured on Sabouraud dextrose agar (SDA) for 24 h at 37°C. The inoculum 
was prepared by McFarland and the exact quantity of organisms was determined by performing 
quantitative cultures. 
Antifungal agents. Fluconazole was obtained in liquid form (2000 μg/ml, Teva Pharma AG, 
Aesch, Switzerland). Amphotericin B (Sigma, St Louis, MO, USA) and caspofungin (Merck & Co., Inc. 
Whitehouse station, NJ, USA) were obtained in powder form and dissolved in sterile water. 
Anidulafungin was kindly provided in powder form by Pfizer Pharma AG (Ecalta, Zurich, 
Switzerland) and dissolved according to the manufacture instructions.  
In vitro antifungal susceptibility. The minimal inhibitory concentration (MIC) was determined by 
microbroth dilution. Antifungal susceptibility of planktonic C. albicans was determined by 
microbroth dilution method according to the EUCAST guidelines (16). 100 µl of a final 
concentration of 1-5 x 105 CFU/ml in RPMI-1640 (Roswell Park Memorial Institute) were added to 
100 µl of a serial two-fold dilutions of each antifungal previously prepared. Plates were 
subsequently incubated at 37°C for 24h and read by spectrophotometer at 530 nm. The MIC was 
defined as the lowest antifungal concentration inhibiting 50% of growth. Experiments were 
performed in triplicates 
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Animal model. A foreign-body infection model in guinea pig was used, as described 
previously (17). In brief, male albino guinea pigs (Charles River, Sulzfeld, Germany) were 
kept in the Animal Facility of the University of Lausanne, Switzerland. The experiments were 
performed according to the regulations of Swiss veterinary law. Guinea pigs were weighted 
every week to ensure their well-being. Animals were anesthetized with a subcutaneous 
injection of ketamine and xylazine. Four sterile polytetrafluorethylene (Teflon) cages (32 x 
10 mm) with 130 regularly spaced perforations of 1 mm diameter (Angst-Pfister AG, Zürich, 
Switzerland) were subcutaneously implanted in flanks of the guinea pigs (450 – 550 g) under 
aseptic conditions. Two weeks after implantation, cage fluid was aspirated to confirm 
sterility. Contaminated cages were excluded from further studies.  
Study of the infection profile. The tissue cage model has never been tested with Candida spp. 
in guinea pigs. Therefore, in the first experiment an infection profile was evaluated. Cages were 
infected by percutaneous inoculation of 200 µl of C. albicans containing 4.5 x 103 CFU/cage (low 
inoculum), 4.8 x 105 CFU/cage (intermediate inoculum) and 6.2 x 106 CFU/cage (high inoculum). 
The infection was confirmed by aspiration of the cage fluid and quantification of the culture on 
SDA plates. Planktonic Candida was quantified in aspirated cage fluid on day 1, 2, 3 and 6 (in 
CFU/ml), and clearance rate (in %) in cage fluid was determined. On day 6, the animals were 
sacrificed and the cages were aseptically removed and cultured in 5 ml Sabouraud dextrose broth 
(SDB) for 48 h to determine the spontaneous cure rate of Candida biofilm (in %). Aliquots of 100 
µl were spread on a Sabouraud plates and incubated at 37°C for additional 48 h to evaluate the 
biofilm presence. 
Pharmacokinetic studies. Cage fluid was aspirated in uninfected animals during 48 h (1, 2, 4, 8, 
24 and 48 h) following intraperitoneal administration of a single dose of fluconazole (8 and 16 
mg/kg), amphotericin B (0.62 and 1.25 mg/kg), caspofungin (1 and 2.5 mg/kg) and anidulafungin 
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(6 and 12 mg/kg). For each antifungal dose three guinea pigs were used (i.e. 12 cages). At each 
time point, 150 µl aliquots of cage fluid were aspirated from one cage from each animal (three 
replicates par time point and drug dose). Contaminated cages were excluded from further studies. 
The collected fluid was centrifuged (4500 rpm for 5min at 4°C) and the supernatant was stored at 
-20°C until further analysis. 
Pharmacokinetic parameters were calculated for each animal: Cmax was defined as the maximum 
concentration observed, Tmax was defined as the time needed to achieve the maximum 
concentration, Cmin24 was defined as the concentration measured at 24 h, Cmin48 was defined as 
the concentration measured at 48 h, AUC0-24 and AUC0-48 (area under the curve) were estimated 
by trapezoidal method after 24 h and 48 h, respectively. Variability of PK parameters was 
expressed as mean ± standard deviation. Antifungals concentration profiles were plotted with 
GraphPad Prism version 6.01, using mean of each sampling time per group, with errors bars 
representing standard deviation (SD). 
Pharmacokinetic analysis. Pharmacokinetic studies were performed using a liquid 
chromatography tandem mass spectrometry assay (LC tandem MS assay). Calibration curves 
were established with matrix-matched samples using blank guinea pigs samples spiked with 
relevant concentration of fluconazole, anidulafungin and caspofungin. This aimed at circumventing 
the matrix effect of complex biological fluids that potentially adversely affect the performance of 
the LC tandem MS assay.  
Antifungal treatment in animals. For treatment studies animals were infected with the low 
inoculum (2 x 104 CFU/ml, corresponding to 4 x 103 CFU/cage). Antifungal treatment started 12 h 
after infection. Cage fluids were aspirated and plated for quantitative analysis, followed by the 
antifungal treatment. Three animals, each animal holding 4 cages (i.e., 12 cages/treatment 
regimen), received one of the following treatment regimens: control group (no antifungal 
treatment); fluconazole (16 mg/kg); amphotericin B and caspofungin (2.5 mg/kg) and 
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anidulafungin (20 mg/kg). All antifungals were administered intraperitoneally every 24 h for 4 days. 
The antifungal dose was chosen based on pharmacokinetic studies performed in previously 
reported studies on rats, mice, guinea pigs and humans.  
Activity on planktonic and biofilm C. albicans in animals. To determine the activity of 
antifungals against C. albicans, cage fluid was aspirated before (to confirm the presence of 
infection), during and 10 days after treatment. The fungal counts were expressed as log10 CFU/ml 
cage fluid. To determine the activity against C. albicans biofilm, animals were sacrificed 10 days 
after treatment and the cages were explanted under aseptic conditions and incubated for 48 h in 
5 ml of SDB. After 48 h, 100 µl were spread on a blood agar plate and incubated at 37°C for 
additional 48 h and assessed for fungal growth.  
Statistical analysis. Comparisons were performed by using the Mann-Whitney U test for 
continuous variables. For all test differences were considered significant when P values were 
<0.05. Figures were plotted with GraphPad Prism (version 6.01) software (GraphPad Software, 
La Jolla, CA). 
 
RESULTS 
In vitro antifungal susceptibility.  The MIC values of C. albicans obtained by microbroth 
dilution were 0.25 µg/ml for fluconazole, 0.25 µg/ml for caspofungin and 0.03 µg/ml for 
anidulafungin.  
Infection profile.  Figure 1 represent planktonic C. albicans in cage fluid after infection with 
103 CFU/cage (A), 105 CFU/cage (B) and 106 CFU/cage (C). A spontaneous progressive reduction 
of the planktonic counts of Candida from tissue cage fluid was observed during 6 days with all 
inocula. On day 6 (just before explantation), C. albicans was cleared from 3/12 cage fluids (25%) 
with low inoculum of 103 CFU/cage and from 1/12 (8%) cage fluids with intermediate inoculum of 
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105 CFU/cage. No clearance was observed with the high inoculum of 106 CFU/cage. After 
explantation of the cages one week after infection, biofilm was detected in all 12 cages, proving 
the presence of biofilm. No sign of skin inflammation or perforation of the cage was seen during 
the infection profile.  
Pharmacokinetic studies.  Figure 2 shows the concentration-time profile in cage fluid after 
the administration of a single intraperitoneal dose in non-infected animals. Table 1 summarizes 
the calculated pharmacokinetic parameters. The Cmax of fluconazole after the administration of a 
single intraperitoneal dose of 8 and 16 mg/kg were 3.64 µg/ml and 9.07 µg/ml, respectively, which 
were achieved at ≈6.7 h after dosing. At 8 mg/kg, the fluconazole maximum concentration in the 
cage fluid reached 14X the MIC of the tested organism (0.25 µg/ml), whereas at 16 mg/kg it 
reached 36X the MIC. The fluconazole concentrations remained above the MIC for 24 h (Cmin24, 
1.14 and 2.90 µg/ml for doses of 8 and 16 mg/kg, respectively) and decreased below the MIC at 
48 h at 8 mg/kg (Cmin48, 0.20 µg/ml). 
The Cmax of caspofungin after the administration of a single intraperitoneal dose of 1 and 2.5 mg/kg 
were 0.32 µg/ml and 1.41 µg/ml, respectively, which were achieved at 24 h and 16 h, respectively. 
The maximum concentration in the cage fluid was above the MIC of C. albicans (0.25 µg/ml) at 
both doses. The maximum concentration reached 1 X and 2.8X the MIC at 24 h (Cmin24, 0.32 and 
1.40 µg/ml for doses of 1 and 2.5 mg/kg, respectively). Concentrations were below the MIC at 48 
h at 1 mg/kg (Cmin48, 0.15 µg/ml). 
The Cmax of anidulafungin after the administration of a single intraperitoneal dose of 6 and 12 
mg/kg were 0.15 µg/ml and 0.22 µg/ml respectively, which were achieved at 6.0 h and ≈13.3 h, 
respectively. At 6 mg/kg, the maximum concentration in the cage fluid reached 5X the MIC (0.03 
µg/ml). The maximum concentration reached 7X the MIC at 12 mg/kg. The anidulafungin 
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concentrations remained above the MIC for 48 h (Cmin48, 0.04 and 0.06 µg/ml for doses of 6 and 
12 mg/kg, respectively).  
Antifungal treatment in animals . Cage fluid sterility was confirmed prior to infection. At 
12 h after infection, the median (± SD) concentration of the yeast in the cage fluid was 1 x 103 
CFU/ml (2.73 ± 0.68 log10 CFU/ml) before treatment. In control animals receiving no drug, fungal 
counts in cage fluid were 2.22 ± 0.8 log10 and 0.70 ± 1.17 log10 CFU/ml after 4 and 14 days, 
respectively, which correspond to decrease of 0.51 and 2.03 log10 CFU/ml, respectively. No 
spontaneous cure of the cage-associated infection occurred in the untreated animals. 
Activity on planktonic and biofilm C. albicans  in animals. Before treatment, cage 
fluid contained (2.73 ± 0.68 log10 CFU/ml) 1 x 103 C. albicans/ml. Compared to untreated control, 
fluconazole and amphotericin B did not reduce planktonic C. albicans during and after treatment, 
whereas caspofungin reduced the numbers to 0.22 ± 0.51 and 0.0 CFU/ml and anidulafungin to 
0.11 ± 0.38 and 0.13 ± 0.46 CFU/ml cage fluid (Fig. 3). No spontaneous cure occurred in the 
untreated controls (Fig. 4), whereas fluconazole cured 2 of 12 cages (17%), amphotericin B and 
anidulafungin 1 of 12 cages (8%) and caspofungin 3 of 12 cages (25%). 
 
DISCUSSION 
The biofilm formation in Candida spp. is increasingly recognized as a significant clinical problem, 
especially in transplant, oncology and intensive care medicine (18). Implant-associated infections 
caused by yeasts are particularly characterized by high complexity and treatment challenges due 
to often concomitant immunosuppression of the patient, antifungal resistance and limited 
therapeutic options against Candida biofilms. Data on optimal antimicrobial and surgical 
management of implant-associated infections caused by Candida spp. are limited (19). In most of 
the cases, explantation of the device is performed, followed by long-term antifungal treatment. 
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However, the outcome is often characterized with relapses, persistent infection and need of 
multiple radical surgical interventions.  
Azoles, the most studied antifungal agents, especially fluconazole, demonstrated low activity 
against Candida biofilms (20-23). Sessile yeast cells could grow, proliferate and form biofilms after 
1 h of adherence despite the presence of high concentrations of fluconazole up to 1024 µg/ml 
(24). In a time-kill study, fluconazole showed lacking ability to eradicate Candida biofilm, whereas 
caspofungin and amphotericin B deoxycholate showed good activity over 48 h (25). In several 
studies echinocandins showed superior in vitro activity against Candida biofilms than azoles (26, 
27), as was also showed in a recent study using the ultra-sensitive microcalorimetry assay (Maiolo 
E et al., manuscript AAC01815-13, in revision). 
In this study, we therefore evaluated the in vivo activity of antifungals in an established foreign-
body model using guinea pigs, specifically against planktonic and biofilm C. albicans. Several 
interesting observations were made. During the study of the infection profile of C. albicans in 
untreated animals, a spontaneous decrease of the number of inoculated planktonic C. albicans in 
the cage fluid was observed. Particularly at low inoculum, some cage fluids cleared planktonic 
Candida from the cage fluid completely. However, when infected cages were explanted, all cage 
cultures grew Candida independently on their inoculum size (low, intermediate or high). This 
observation supports the hypothesis that Candida switch from planktonic into biofilm form when a 
foreign body is present in order to persist on the surface of the cages. Since there was no 
spontaneous cure of Candida biofilms, this model is suitable to test the activity of individual 
antifungals against biofilms. 
The pharmacokinetics of tested antifungals was characterized to determine the appropriate dosing 
and administration intervals. After 24 h of administration, the concentration of all four tested 
antifungals in the cage fluid was above the MIC of the test organism, whereas after 48 h with 
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fluconazole at 8 mg/kg and caspofungin at 1 mg/kg the concentrations in cage fluid were below 
the MIC. Therefore, the once-daily doing was chosen for further experiments.  
In treatment studies, fluconazole and amphotericin B did not reduce planktonic C. albicans in the 
cage fluid during and after treatment and showed limited anti-biofilm activity with cure rates from 
8% to 17%. In contrast, caspofungin and anidulafungin had a superior activity against planktonic 
Candida in the cage fluid. Against C. albicans biofilm, anidulafungin exhibited similar activity than 
amphotericin B (cure rate 8%), whereas caspofungin showed superior activity against C. albicans 
biofilm (cure rate 25%).  
The observed antifungal activity is in general lower than the one of antibacterial substances 
against S. aureus, E. coli, Enterococcus faecalis or P. acnes (12-15) using the same foreign-body 
infection model. This fact underlines that Candida remains a difficult-to-treat organisms and 
removal of a device with staged concept of re-implantation seems to be the rational treatment 
strategy. Other treatment strategies, such as novel antifungals, combination therapies or 
mechanical (e.g. sonication), biological (e.g. phages) or chemical (e.g. enzymes) biofilm removal 
strategies may improve the treatment outcome and make the retention and salvage of an infected 
prosthesis possible.  
In conclusion, caspofungin and anidulafungin showed superior activity against planktonic C. 
albicans compared to amphotericin B and fluconazole at physiological doses. No antifungal drug 
administered alone achieved cure rates above 25%, demonstrating the difficulty of eradicating 
Candida biofilms from implants. In further studies, higher doses of the antifungals, their 
combinations or addition of a non-pharmacological approach may improve the treatment outcome 
and can help planning rational clinical trials in implant-associated infections. 
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Figure 1. Infection profile, i.e. planktonic C. albicans in cage fluid after infection with 103 CFU/cage 
(A), 105 CFU/cage (B) and 106 CFU/cage (C). Horizontal lines represent means, numbers 
represent mean ± standard deviation values (in log10 CFU/ml cage fluid).  
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Figure2. Pharmacokinetic profile of fluconazole, caspofungin and anidulafungin in cage fluid after 
the administration of a single intraperitoneal dose of the drug in non-infected animals. The mean 
values of three measurements (except for caspofungin and anidulafungin 6 mg/kg, 2 
measurements were considered) at each time point are shown. Points represent means; error 
bars represent SDs. 
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Figure 3. Activity against planktonic C. albicans in cage fluid during (day 4) and after 
treatment (day 14). Animals were infected with 2 x 104 CFU/ml, corresponding to 4 x 103 
CFU/cage. Numbers above error bars represent mean log10 CFU/ml ± standard deviations (SD) 
of antifungal treatments (AMB= amphotericin B; FZL= fluconazole; CAS = caspofungin; AFG= 
anidulafungin).  
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Fig. 4. Treatment efficacy against biofilm C. albicans. Numbers in brackets are number of 
cured / number all cages, followed by the cure rate of biofilm Candida (in %). 
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Table 1. Pharmacokinetic parameters for the drugs tested in cage fluid after administration of a single intraperitoneal dose to non 
infected animals. 
 
Antifungal MIC 
(µg/ml) 
Dose 
(mg/kg) 
Cmax 
(µg/ml)a 
Cmin (µg/ml)a Tmax (h)a Cmin24h 
(µg/ml)a 
Cmin48h (µg/ml)a AUC0-24 
(h·µg/ml)a 
AUC0-48 
(h·µg/ml)a 
Fluconazole 0.25 
8 3.64 ± 0.10 0.20 ± 0.07 6.67 ± 2.31 1.14 ± 0.02 0.20 ± 0.07 62.80 ± 2.68 78.92 ± 2.58 
16 9.07 ± 1.14 0.49 ± 0.37 6.67 ± 2.31 2.90 ± 0.68 0.49 ± 0.37 146.10 ± 8.55 186.79 ± 3.02 
Caspofungin 0.25 
1 0.32 ± 0.01 0.15 ± 0.05 24 ± 0.00 0.32 ± 0.01 0.15 ± 0.05 4.54 ± 0.66 10.18 ± 0.21 
2.5 1.41 ± 0.23 0.46 ± 0.01 16 ± 11.31 1.40 ± 0.22 0.46 ± 0.01 25.43 ± 7.54 47.77 ± 10.23 
Anidulafungin 0.03 
6 0.15 ± 0.05 0.04 ± 0.01 6 ± 2.83 0.10 ± 0.04 0.04 ± 0.01 2.68 ± 1.07 4.35 ± 1.64 
12 0.22 ± 0.07 0.06 ± 0.01 13.33 ± 9.24 0.18 ± 0.10 0.06 ± 0.01 4.25 ± 1.50 7.11 ± 2.69 
aValues are means ± SDs from three animals. 
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Chapter5. General conclusions and outlook 
The development of reproducible reference methods for in vitro testing of antifungal agents against 
Candida spp. has been a significant step in the improvement of treatment efficacy. The importance 
of antifungal susceptibility testing is indeed continuously increasing by the emergence and spread 
of resistant strains. Several sibling genes implied in azoles resistance have been identified leading 
to a reduced susceptibility to these agents. Thus, studies on new agents and their activity are of 
great importance. Current biofilm tests are questioned regarding their validity and reproducibility. 
Most of the tests include a continuous handling and addition of reagents that could destroy the 
biofilm structure, therefore, a more easy-to perform method needs to be developed. 
Isothermal microcalorimetry is commonly used for analysis of chemical and biochemical reactions, 
either consuming or producing energy. During the last decade, the utility and advantages of 
isothermal microcalorimetry for highly sensitive detection of microbial growth was demonstrated 
for a range of microorganisms. In a clinical setting, microcalorimetry was shown to be useful for a 
rapid detection and discrimination between culture positivity and negativity of fluid samples. In 
Chapter 3 we demonstrated the potential of isothermal microcalorimetry as a novel method for 
antifungal susceptibility testing of Candida spp. Microcalorimetry showed the potential to be a 
suitable and precise method for performing antifungal susceptibility testing, as data is obtained 
continuously in real-time and the test interpretation is not based on subjective visual examination 
or by spectrophotometry. We demonstrated that fluconazole, echinocandins and amphotericin B 
affected the growth-related heat production of Candida spp. in different ways, depending on their 
fungistatic or fungicidal properties and phenomena, such as the paradoxical growth, could also be 
monitored. The MHIC was determined as the lowest concentration inhibiting ≥50% (≥90% for 
amphotericin B) of the heat produced at 24 h or 48 h for planktonic and biofilm growth, 
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respectively. For Candida spp., agreement within two 2-fold dilutions between MHIC (by 
microcalorimetry) and MIC (determined by EUCAST guideline) was 50% for fluconazole and 
100% for echinocandins and amphotericin B. In order to validate our biofilm assay, XTT testing 
for biofilm growth evaluation was included. The agreement within two fold dilutions between the 
MHIC and the XTT test at 24h was 75% for fluconazole and 100% for echinocandins and 
amphotericin B. As determined by microcalorimetry, echinocandins were the most active agents 
against planktonic Candida spp (MHIC 0.015-0.5 μg/mL). Echinocandins, especially 
anidulafungin, also showed to have a good activity against biofilm growth (MHIC 0.25-2 μg/mL).  
The conventional microbroth dilution method requires experienced personnel and especially in the 
case of CLSI the interpretation of susceptibility data is fairly subjective. Microcalorimetry, in 
contrast, offers an objective approach for data interpretation, based on heat production and change 
in the calorimetric curve, associated with the inhibition of growth. Considering the advantage of 
real-time growth monitoring, the microcalorimetric assay could be further optimized for a rapid 
detection of resistant isolates. Indeed, in a future study we will screen a strain collection of different 
azole-resistant Candida isolates, with the goal to establish a rapid and sensitive assay for detection 
of azole resistance, as was previously described for the differentiation between methicillin-
susceptible and methicillin resistant S. aureus and for the determination of susceptibility of 
Aspergillus species using the same methodology (Furustrand, 2012). Furthermore, we will evaluate 
the activity of antifungal combinations against Candida spp. by microcalorimetry and compare it 
with the standard in vitro methods used for synergy testing, the time-kill and the checkerboard 
microdilution methods.  
The use of porous glass beads for biofilm formation showed to be a practical and easy method for 
the evaluation of biofilm growth, without too much handling (which could alter the biofilm). The 
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addition of dyes or other agents, as in the case of the crystal violet staining (which gives a rough 
estimation of biofilm mass and differentiate between biotic and abiotic material but it does not give 
information about viability or activity) could also be avoided. In a future study we will test different 
materials, with the goal to establish a sensitive assay for detection of biofilm growth and inhibition 
by antifungals and by the material itself.  
Considering a future use of microcalorimetry in a clinical microbiological laboratory, several topics 
need to be taken into account. First, the currently used isothermal microcalorimeter is still too 
expensive, mainly due to the low production volume. In order to lower the cost of the instrument 
it needs to be simplified and adapted to the current microbiological test conditions. Second, the 
instrument needs to allow a semi- or fully automated processing of multiple samples enabling high-
throughput testing and biofilm testing. Promising developments in the calorimetric instrument field 
need to be performed as the high-throughput measurement calorimeter made by Torres in 2004. He 
presented a low-cost nano-calorimeter able to detect enthalpies of binding, enzymatic turnover and 
other chemical reactions in arrays of 96 positions. Adaptations in the development of high-
throughput biofilm research also need to be performed in order to meet these criteria. 
Based on in vitro results, we investigated the different treatment regimens in a guinea-pig model 
of foreign-body infections. Experimental conditions were assessed and optimized based on 
previous studies performed on mice, rats and guinea pigs found in the literature. A low inoculum 
and a short duration of infection (12h) were used for C. albicans, since treatment failure occurred 
when using high inoculum (106), 24 h of inoculation and low antifungal doses (data not shown). 
Infection profile experiments showed that a high inoculum is necessary to induce a persistent 
infection without spontaneous cure of planktonic yeast in cage fluid, nevertheless, antifungals 
showed no activity on planktonic cells in the cage fluid nor on the biofilm when using a high 
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inoculum. Since there was no spontaneous cure of Candida biofilms, this model is suitable to test 
the activity of individual antifungals against biofilms. However, using a low inoculum, an 
intermediate duration of infection and higher antifungal concentrations, a reduction of planktonic 
C. albicans was observed when echinocandins were used compared to other treatment regimens.  
We were able to confirm our in vitro findings in vivo by performing treatment studies. The best 
activity was shown with caspofungin and fluconazole with a cure rate of 25%. Pharmacokinetic 
analysis highlights the importance of giving a good treatment regimen in order to achieve a local 
antifungal concentration above the MIC, since sub-MIC concentration can cause to resistance. 
Considering the growing number of implant-associated infections, as well as the increasing 
prevalence of antimicrobial resistance, combination therapy could be an alternative, as well as new 
different treatment strategies for biofilm infections. Another approach could be the prevention of 
microbial attachment by manipulating the surface of the implant without influencing the host 
biocompatibility. Several studies are ongoing in this field trying to coat the implant surface with 
antimicrobials, embed the device and the spacers use in orthopedic surgery with antimicrobial 
substances, or by rendering the surrounding fluid less acid by ions release from the material leading 
to an inhibition of biofilm formation. Nevertheless, as already mentioned, sub-MIC concentration 
of the antimicrobial could lead to microorganism resistance.  In order to avoid the emergence of 
resistance, early inhibition of cellular attachment on the device and biofilm formation, or even 
enzymatic degradation of biofilm, when present, could represent new strategies to improve the 
eradication of the infection. 
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Chapter6. General introduction 
Since bacteria can exist as single cells (planktonic) or in sessile aggregates (biofilm), the primary 
bacterial adherence to the foreign-body surface starts with planktonic cells and is followed by an 
irreversible attachment and maturation in a complex three-dimensional structure known as biofilm 
(Figure 1). The definition of a bacterial biofilm, as for medical microbiology, is a “coherent cluster 
of bacterial cells imbedded in a matrix, which are more tolerant to most antimicrobials and the host 
defense, than planktonic bacterial cells” (1). Within the biofilm cells communicate through 
intercellular signaling described as “quorum sensing” (2), which leads to structural and functional 
heterogeneity of the biofilm. From the mature biofilm, planktonic bacteria detach and depending 
on their virulence could cause either a local or a systemic infection (3, 4).  
 
 
Figure 1. The biofilm life cycle. A biofilm starts to form when bacteria attach to a surface (1 min). An irreversible 
attachment (3 min) leads to the biofilm maturation through growth of the bacterial cells and production of the complex 
three-dimensional extracellular matrix (12 h to 3 days). Planktonic bacteria can detach and spread from the biofilm. 
(Adapted from K. Kasnot, Scientific American, 2001). 
The biofilm matrix composed by extracellular polymeric substances (EPS) constitutes an excellent 
survival mechanism for the pathogen, in which bacteria are protected from the host immune system 
and the most used antimicrobial agents (2, 5, 6). Moreover, depletion of metabolic substances 
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and/or waste product accumulation in biofilms causes microbes to enter a slow- or non-growing 
(stationary) state. The most common infecting microorganisms causing implant-associated 
infections are staphylococci, followed by coagulase negative staphylococci, etc.(7, 8). Table 1 
reports the most common pathogens isolated from prosthetic infections (9). 
 
Microorganism       Frequency (%) 
              
Staphylococcus aureus 
  
30-43 
 
Coagulase-negative staphylococci 
 
17-21 
 
Gram-negative bacilli 
  
5-13 
 
Polymicrobial 
   
5-14 
 
Anaerobes 
   
2-5 
 
Enterococci 
   
3-7 
 
Streptococci 
   
11-12 
 
Other/Unknown 
   
5-6 
 
              
 
Table 1. Frequency of most common identified microorganisms causing prosthetic joint associated infections. 
Adapted from (9)  
 
Rare are the infections associated with orthopedic devices like calcium phosphate (CaP) bone 
grafts, but when it occurs it represents a devastating complication with high morbidity and 
substantial costs  since implant-associated infections are typically caused by microorganisms 
growing in biofilms (10). The eradication of infection is often only possible by removal of the 
implant and long-term antimicrobial treatment (11). Determining the risk of infection as well as 
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the evaluation of efficient treatment options and outcome and the infections characteristics is of 
considerable clinical relevance. 
 
BONE GRAFT 
Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures 
that are extremely complex, cause a significant health risk to the patient, or fail to heal properly. 
More than one million patients per year need a bone grafting surgery in order to repair a bone defect 
resulting from a bone disease or a trauma (12-14). Bone transplantation is performed about 10-
times more often than any other solid organ transplantation and is the most commonly performed. 
The use of bone graft is increasingly used in orthopedic surgery to fill bone defects or as 
antimicrobial delivery system (15), therefore, there is a high probability that infections associated 
with such devices could also increase. Bone has the ability to regenerate completely but to do so it 
requires a very small fracture space or some sort of scaffold. Bone grafts should have the 
characteristic of being completely reabsorbed and replaced as the natural bone heals over a few 
months.  
The main type of bone grafts are (16):  
1. Autologous (or autogenous) is a bone obtained from the patient’s own body, often from iliac 
crest or the proximal tibia. It is also the most preferred due to the less risk of graft rejection since 
the graft originated from the same individual receiving the graft. A negative aspect is that an 
additional surgical site is required, which could leads to additional post-operative pain and 
complications. 
 2. Allograft is a bone obtained from cadavers, usually sourced from a bone bank, implying that 
the allograft is harvested from another individual than the one receiving the graft.  
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3. Synthetic variants are artificial bones created with similar mechanical properties of the bone. 
They are often created from ceramics such as calcium phosphate, Bioglass and calcium phosphate 
(e.g. hydroxyapatite (HA), tricalcium phosphate or other biocompatible substances). A positive 
aspect is that the mechanical properties are comparable to bone. Furthermore, growth factors can 
be added to the materials or mixed with bone marrow in order to increase the biological activity. 
Infection and rejection of the graft is also less of a risk and no additional surgical site is required.   
 
Biological mechanisms 
The main biological mechanisms of bone grafts are the following: 
Osteoconduction. Osteoconduction occurs when the bone graft material serves as a scaffold for 
new bone growth. The bone graft material is used as a framework from osteoblast located in the 
margin of the defect bone. 
Osteoinduction. Osteoinduction occurs when osteoprogenitor cells are stimulated to differentiate 
into osteoblast which enables the new bone formation. 
Osteogenesis. In this case osteoblasts are originating from the bone graft material. Osteogenesis 
occurs when these osteoblast contribute to the growth of new bone in parallel with bone growth 
generated by the other mechanisms. 
Osteopromotion. Osteorpomotion occurs when osteoinduction is enhanced without having an 
osteoinductive property. 
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Nowadays, the use of synthetic bone graft substitutes is replacing the traditional golden standard 
of autogenous bone grafting (12, 17, 18). In surgery procedure like filling fracture defects, reunion 
of long-bone, total joint revision or spine fusion, synthetic bone grafts substitutes are expected to 
be a safer and effective option (19).  
 
BIOMATERIALS 
A biomaterial is a synthetic material to be used in intimate contact with living tissue. A more 
precise definition of a biomaterial was given in 1986, at the Consensus Conference of the European 
Society for Biomaterials, when a biomaterial was firstly defined as "a nonviable material used in a 
medical device, intended to interact with biological systems". A definition that evolved within 
years until the last given in 2011 as “material intended to interface with biological systems to 
evaluate, treat, augment or replace any tissue, organ or function of the body” (European society for 
biomaterials (ESB), 1976). 
The use of synthetic materials with the purpose to replace parts of the human body is old of ages. 
Gold dental prosthesis has been found in some Egyptian mummies. In the pre-Christian era the 
gold standard ‘biomaterials’ were copper and bronze. Those materials were subsequently causing 
problems because of their toxicity. The introduction of aseptic conditions in surgery in 1860 was 
a step forward in the improvement regarding the application of biomaterials. Since then, different 
materials were manufactured and used (as ivory or metallic prostheses, gold capsules, etc.).  
Polymethilmethacrilate (PMMA) began to be used in 1930 to anchor metallic prosthesis to bone 
and generate a permanent implant. One of the problems most encountered in orthopedic devices 
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is the biochemical compatibility at the interface between synthetic material and living tissue. 
Researchers are since then working to find stables and inert materials for devices.  
In the past, ceramics and glasses were also commonly used in a wide range of medical-related 
applications, as for example eye glasses, chemical and chirurgical glassware or even in dentistry. 
The use of ceramic components inside the body is relatively new and nowadays, bioceramics are 
widely used for different applications inside the human body (Figure 2) (20). 
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Figure2. Clincal uses of bioceramics. From (20). 
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BIOACTIVE GLASS 
“The human body rejects metallic and synthetic polymeric materials by forming scar tissue because 
living tissues are not composed of such materials. Bone contains a hydrated calcium phosphate 
component, hydroxyapatite and therefore if a material is able to form a HA layer in vivo it may not 
be rejected by the body” was the hypothesis at the basics of the bioactive glass discovery and 
production made by Professor Hench in 1968. 
Biocompatible tissue-bonding bioactive glasses (BAGs) are a group of synthetic silica-based 
bioactive materials with the unique bone bonding characteristic. This property was first discovered 
by Hench in the 1970s (21). The first bioactive glasses were composed of four-component system: 
SiO2,Na2O, CaO and P2O5, as found for example in bioglass 45S5 and S53P4 and the weight 
percentages of these oxides vary in different glasses (20). These glasses show a tendency to 
crystallization at high temperatures, therefore, to overcome this disadvantage, new bioactive 
glasses have been developed based on the Na2O-K2O-MgO-CaO-B2O3-P2O5-SiO2 system (22). By 
this way it is possible to manufacture the glasses into different shapes as microspheres, fibers and 
porous implants leading to an additional advantage for the clinical use. In this study the bioglass 
S53P4 was tested since it is commercially available for treatment of bone defects. 
 
Molecular mechanism  
The chemical surface reaction is initiated as soon as the bioactive glass is in contact with body 
fluids. Within the first hour ions are released (Na, Ca, P, Si) from the bioactive glass surface leading 
to an increasing of the pH and the osmotic pressure (Figure 3). After only one day the silica gel 
layer forms on granule surface through polycondensation of the hydrated silica groups. The Ca2+ 
and PO43+ precipitate from the extracellular fluids onto the Silica rich layer (19, 23). Within one 
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week CaP crystallizes to natural hydroxyapatite. The bioactive glass bonds to the bone and 
promotes the oesteointegration.  
 
 
Figure3. Surface reaction cascades. The release of ions (Na, Ca, P, Si) increases the pH and the osmotic pressure, 
takes place within 1 hour and leads to an inhibition of bacterial growth on granule surface. Silica gel layer forms on 
granule surface and CaP precipitate on the surface (1 day). Within one week CaP crytallizes to HA enabling bone 
bonding. (Adapted from the brochure of BonAlive) 
  
 
Compared with synthetic bioresorbable bioactive ceramics, such as HA, calcium phosphate and 
tricalciumphosphate, which are the most commonly used osteoconductive bone grafts substitutes 
(24, 25), silica-based bioactive glasses form themselves a group of bioceramics with unique 
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properties such as the osteopromotive ability, dissolution or more the inhibition of bacterial growth 
previously shown in vitro (Table 2). 
 
Table 2. Comparison of synthetic HA/TCP and bioactive glasses as bone graft substitutes. Adapted from (19). 
Nowadays BAGs are gaining use in both dental and orthopedic applications. Since the 1980s they 
have been applied in several surgeries such as the reconstruction of orbital floor fractures and 
defects of facial bones, in filling of frontal sinuses, in treatment of depressed tibial plateau fractures 
and  in treatment of osteomyelitis (26-31). BAG S53P4 has been shown to have an angiogenesis-
promoting properties and an antibacterial effect on some oral microorganisms as well as on a 
variety of clinically important aerobic and anaerobic pathogens (32-37). Several factors contribute 
to the antibacterial action of BAGs as the osmotic effects caused by the concentrations of ions 
dissolved from the glass and the increasing pH (20, 35). 
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ABSTRACT 
We tested the activity of bioactive glass (BAG) S53P4 on planktonic microorganisms using a highly 
sensitive assay measuring growth-related heat production (microcalorimetry). BAG was tested in 
different granule sizes (0.5-0.8 mm and <45 µm) and volumes (1 and 2 g).  
S. aureus (ATCC 29213), S. epidermidis (ATCC 35984), E. faecalis (ATCC 19433), E. coli (ATCC 
25922) and C. albicans (ATCC 90028) were tested. Test strains were added in sealed glass 
ampoules containing 2, 25 ml Müller Hinton broth with or without BAG and placed into the 
microcalorimetry at 37°C. The heat flow produced was recorded by microcalorimetry and the total 
heat analysed. The heat flow pick decreased with the addition of different volumes BAG 0.5-0.8 
mm, except for E. coli where a higher production of heat was detected. The heat flow pick 
decreased for all the microorganisms tested when <45 µm BAG was used.  
BAG <45 µm showed a better activity against all the microorganisms than BAG 0.5-0.8 mm, this 
phenomena was better shown when analysing the area under the curve and by taking into account 
the heat produced by the controls. Microcalorimetry allowed real-time evaluation of antibacterial 
activity of bioactive glass.  
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INTRODUCTION 
A new era in development of materials for use in medicine began in the 1970s, when Professor 
Larry Hench discovered glasses capable of forming interfacial bonding with bone. The 
compositions showing this special property were called bioactive glasses (1). Bioactive glasses 
(BAGs) are a group of surface reactive glass-ceramic biomaterial, which, thanks to their 
biocompatibility, are used as implant materials in the human body to repair and replace diseased 
or damaged bones. The composition of the first bioactive glass, named 45S5, was approved from 
the Food and Drug Administration (FDA), and after the invention of BAG 45S5, numerous glasses 
and glass ceramic with different composition have been developed and studied. 
Bioactive materials are synthetic osteoconductive bone substitutes able to bind chemically to the 
bone, with documented antibacterial and angiogenesis-promoting properties (2-6). The BAG used 
in this study is named S53P4 and it is composed of SiO2 (53%), Na2O (23%), CaO (20%), P2O5 
(4%), which are all naturally found in the human body. BAG S53P4 surface is activated by blood 
or physiological solutions. The first reaction that we can observe, when the glass is in contact with 
a solution, is the exchange of alkalis from the glass surface with H+ and H3O+ in the same solution. 
The siloxane bonds in the glass interface subsequently starts breaking, leading to loss of soluble 
silica in the form of Si(OH)4 in the solution. In the following step, the thickness of the silica rich 
layer is increased, thanks to the condensation and repolymerization of a SiO2 rich layer on the 
surface. The layer grows by incorporation of Ca2+ and PO24 ions from the solution: the CaP-layer 
mineralizes to natural hydroxyapatite, which will bond to the surrounding bone. The hydroxyapatite 
starts forming in a few hours, within 3-6 weeks osteogenic cells are organizing osteoid tissue 
between the granules and, in about 6-8 weeks, the lamellar bone is formed. On the other side, the 
presence of those ions can inhibit bacteria growth. Two principal mechanisms give rise to the 
bacterial growth inhibiting property and prevent the bacteria to attach on the surface: 1) the release 
of sodium (Na) and the subsequent formation of NaOH, increases slightly the pH (9-11) in the 
close vicinity of the surface of the glass. 2) the increasing of the osmotic pressure, which occures 
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when other ions, Ca, Si and P, are released (4). Several studies have been performed in vitro and 
in vivo to assess the best structrure fro the activity of the bioactive glass to satisfy the biological 
and medical need (6-13). 
The purpose of this study was to evaluate the activity of BAG S53P4 and different parameters 
(amount and size) on planktonic S.aureus, S. epidermidis, E. faecalis, E. coli and C. albicans and 
by microcalorimetry. 
 
MATERIALS AND METHODS 
Test strains. S. aureus (ATCC 29213), S. epidermidis (ATCC 35984), E. faecalis (ATCC 19433), 
E. coli (ATCC 25922) and C. albicans (ATCC 90028) were used. Stocks of each strain were 
maintained on cryovials (Roth, Karlsruhe, Germany) at -80°C. Bacteria were cultured on MH agar 
plates, Candida was cultured on Sabouraud dextrose agar (SAB) for 24 h at 37°C. Inoculum was 
prepared by McFarland and the exact inoculum was determined by quantitative cultures. The final 
concentration in the ampules, filled with 2,25 ml MH, was ~105 CFU/ml.  
Materials. The BAG S53P4 powders (BonAlive Biomaterials Ltd, Finland) were produced by 
Process Chemistry Center, Åbo Akademi University, Turku. Tested granules of BAG S53P4 used 
have two different sizes, 0.5-0.8 mm and <45 µm. The composition of this synthetic material is, by 
weight, SiO2 53%, Na2O 23%, CaO 20%, P2O5 4%. For each experiment we used 1 or 2 g of 
bioactive glass in each ampule. 
Evaluation of thermal growth characteristics. An isothermal microcalorimeter (TAM III, TA 
Instruments, Newcastle, DE), equipped with 48 calorimeters and a detection limit of heat 
production of 0.2 µW was used. The ampoules were air-tightly sealed and introduced into the 
microcalorimeter, first in the equilibration position and after 15 minutes in the measuring position. 
Temperature was set at 37°C and heat flow was recorded for 48 h. Calorimetric ampoules (4 ml 
total volume) containing 2,25 ml of MH media and 1 or 2 g BAG were inoculated with 106 CFU/ml. 
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For the negative control the ampoules were filled with 2,5 ml BHI and 1 or 2 g of BAG. The growth-
related heat production of tested bacterial strains was investigated. Heat flow in μW Joule was 
recorded and the total heat in J analysed. 
BAG were also analysed alone without microorganisms addition in order to analyse the heat 
produced by the BAGs. The activity of BAG after 24h were also analysed by leaving the different 
BAGs in MH for 24h before addition of the tested strain (S. aureus in this case). 
Data analysis. Microcalorimetry data analysis was accomplished using the manufacturer's 
software (TAM Assistant, TA Instruments, New Castle, DE). Figures were plotted using 
GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA).  
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RESULTS  
Evaluation of thermal growth characteristics . 
All the experiments were performed in duplicate by microcalorimetry, showing clear results in 
terms of heat production from microorganisms. In order to assess a correlation between the 
amount and sizes of BAG and the subsequent effect on the growth of the microorganisms, different 
sizes of granules (0.5-0.8 mm and <45 µm) and different amounts (1 and 2 g) have been tested. 
The effect of BAG on the growth of the different microorganisms analysed by microcalorimetry is 
shown in Figure 1 and 2. All the volumes and sizes of BAG used inhibited the growth of the tested 
microorganisms, except for E. coli with BAG 0.5-0.8 mm. Figure 1 and 2 also shown the total heat 
(considered as the area under the curve) obtained by microcalorimetry. The analysis of the total 
heat shown, for some experiments (Fig1. A, B, C, D and Fig2. C), that a higher heat is produced 
with 1 or 2 g of BAG compared to the growth control (without BAG). It also shown that, surprisingly, 
the BAG controls alone, in contact with the media, produced some heat (especially shown in 
Figure 4). Therefore, this phenomena was taken into account by subtracting for each experiment 
the heat flow produced by the controls (1 and 2 g), in order to consider only the heat produced by 
the microorganisms itself when added to the different BAG volumes (Fig.3 A and B). BAG 0.5-0.8 
mm had a good activity especially against S. aureus, S. epidermidis and C. albicans (Fig.3A), 
wherease BAG <45 µm shown a very good activity against all the microorganisms (Figure. 3B). In 
order to try to avoid the heat phenomena produced by the BAGs alone we left the different BAGs 
(0.5-0.8 mm and <45 µm; 1 and 2g) in contact with the media for 24h and added S. aureus 
afterwards. The results showed that the heat phenomenon is no more present and that the BAGs 
still have their antimicrobial activity against S. aureus (Fig. 5). 
DISCUSSION 
We examined the antibacterial effect of BAG S53P4 by microcalorimetry on different gram-
positive, such as S. aureus (coagulase-positive), S. epidermidis (coagulase-negative), E. faecalis, 
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on gram-negative bacteria, such as E. coli and a resistant strain, E. coli Bj HDE and on fungi, as 
C. albicans. We evaluated the activity of the glass on planktonic microorganisms by calorimeter, 
testing different parameters as the amount of glass and the size of glass. The tested strains are 
above the most common microorganisms involved in infections against which the glass could be 
used: osteomyelitis (14), tibial plateau fractures (15) and also benign bone tumors (16). Different 
aerobic (5) and anaerobic (4) bacteria have already been tested by flow cytometric (FCM) showing 
a better activity of BAG S53P4 compared to other type of BAGs. The good antibacterial activity of 
BAG S53P4 against planktonic bacteria, as gram+ and gram- is known. Nevertheless, this is the 
first study of BAG activity assessed with microcalorimetry and against fungi. The mechanism of 
action of the glass against microorganisms is due to the high pH and the osmotic pressure created 
in the media surrounding the BAG. Bacteria normally live with an optimal pH about neutral, 
nevertheless, the release of NaOH from the BAG lead to an acid pH around 9-11 (17). All the other 
released ions cause an increasing of the osmotic pressure, leading to the loss of water from the 
cell and perturbations of the membrane potential of the microorganism. 
In these experiments, we found a correspondence between the volumes of glass: the more glass 
we used the more and faster effect we had, especially when BAG <45 µm were used. We tested 
two different sizes of granules, 0.5-0.8 mm and <45 µm, and according to our results the smallest 
one had a better activity than the biggest one, as expected. This can be explained if we consider 
that from a smaller surface we have a faster and easier release of ions and if we consider that the 
smaller are the granules the bigger is the total surface area for a given volume. We also shown 
that BAG alone produced some heat and in order to take this phenomena into account when using 
microcalorimeters, it is suggested to subtract the heat produced by the controls alone or leave the 
granules for 24h alone with the media before adding the microorganisms of interest. 
In conclusion, this study demonstrates the effect of BAG against different species. These 
experiments show the good activity of BAG against S. epidermidis and C. albicans when using 
the larger diameter granules, and against the Gram – bacteria when using the smaller diameter 
 
 
89 
granules. The study also demonstrates the potential of microcalorimetry for real-time analysis. 
Several studies have previously shown the potential of the isothermal microcalorimetry to detect 
growth of different pathogens and determine the minimal hinibitory concentration (MIC) for 
different antimicrobial agents and microorganisms (18-20)  In this study, microcalorimetry allowed 
high precision real-time evaluation of bioactive glass activity against various microbial species. 
Further studies need to be performed against different species, including resistant and anaerobe 
species, against biofilm and combined with antimicrobial drugs in order to have a better overview 
on BAG S53P4 antibacterial activity and his efficacy. 
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Legend to figures 
Figure1. Heat flow (µW) and Total heat (J) for S. aureus (A), S. epidermidis (B), E. faecalis (C), 
E. coli (D) and C. albicans (E) in presence of BAG 0.5-0.8 mm. 
 
Figure2. Heat flow (µW) and Total heat (J) for S. aureus (A), S. epidermidis (B), E. faecalis (C), 
E. coli (D) and C. albicans (E) in presence of BAG <45 µm. 
 
Figure 3: Total heat (J) for different microorganisms in presence of BAG 0.5-0.8 (A) and <45 µm 
(B) when subtracting the heat produced by the control for each experiment. CG, control growth; 
1g, in presence if 1g of BAG; 2g, in presence of 2g of BAG. All the experiments where analysed 
at 24h except for C. albicans where 40h were considered. 
 
Figure 4: Thermodynamic activity of BAG with different sizes and volumes.  
2g 0.5-0.8 mm = adding 2g of BAG 0.5-0.8 mm of size. 1 or 2g <45 µm = adding 1 or 2g of BAG 
<45 µm of size.  
 
Figure 5. BAGs were put in MH for 24h before adding S. aureus. Experiments were performed in 
duplicate, 
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Fig. 1 
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Fig. 2 
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Fig. 3  
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Fig.4 
 
 
 
 
Fig.5 
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Chapter8. General conclusions and outlook 
Isothermal microcalorimetry is commonly used for analysis of chemical and biochemical reactions, 
either consuming or producing energy. During the last decade, the utility and advantages of 
isothermal microcalorimetry for highly sensitive detection of microbial growth was demonstrated 
for a range of microorganisms.  
In chapter 3, we demonstrated the potential of isothermal microcalorimetry, as a novel method for 
antifungal susceptibility testing of Candida spp. In chapter 8,we further evaluated our assay for 
studying the activity of BAG S53P4 against the most important infective microorganisms: gram-
positive bacteria, such as S. aureus (coagulase-positive), S. epidermidis (coagulase-negative) and 
E. faecalis, gram-negative bacteria, such as E. coli and a resistant strain of E. coli Bj HDE (results 
not shown) and fungi, as C. albicans. Due to the different reproduction rates of the microorganisms, 
microcalorimetry appears to be a suitable and precise approach for performing antifungal 
susceptibility testing and inhibition growth testing by other materials, since the test interpretation 
is not based on subjective visual examination or spectrophotometric reading and the data is 
obtained continuously in real-time (as heat-flow curve). Besides enabling microbial rapid growth 
detection, microcalorimetry allowed also the detection of the exothermic reaction of the bioactive 
material, not detected with common used susceptibility testing. 
The mechanism of action of the bioactive glass against microorganisms is due to the high pH and 
the osmotic pressure created in the media surrounding the material. Bacteria normally live with an 
optimal pH about neutral, nevertheless, the release of NaOH from the BAG lead to an acid pH 
around 9-11. All the other released ions cause an increasing of the osmotic pressure, leading to the 
loss of water from the cell and perturbations of the membrane potential of the microorganism. In 
these experiments, we tested two different sizes of granules, 0.5-0.8 mm and <45 µm, and 
according to our results the smallest one had a better activity than the biggest one. When smaller 
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particles are used, cation released from the surface during the reaction seems to be faster, 
therefore, higher values of pH are reached. Furthermore, the surface area increases for small 
particles than for higher diameter ones: the smaller are the granules the bigger is the total surface 
area for a given volume. With these experiments we also could show that bioactive glass alone 
produces heat. 
In summary, this study also demonstrated the good activity of bioactive glass against 
microorganisms growth and the potential of microcalorimetry for real-time analysis. Considering 
the advantage of real-time growth monitoring, the microcalorimetric assay could be further 
optimized for a rapid detection of resistant isolates or anaerobic bacterial. Indeed, in a future study 
we will screen the activity of bioactive glass S53P4 against different anaerobic strains. 
The work presented here represents only a small step towards the goal of understanding the 
interactions between bioactive glasses and microorganisms. Many possible directions can be taken 
as future developments. On one hand, some of the experiments here exposed could be try to be 
reproduced with other types of bioactive glasses, like, for example, bioactive glasses containing 
also other ions in their composition. Others bioactive glasses sizes and volumes could also be tested 
as well as the addition of antibiotics and antifungals, in this case the activity of the antimicrobials 
in a high pH environment should also be assessed. Characterization of the surface interaction sites 
with cells or proteins and simulated body fluids in order to have a higher similarity with the real 
biological situation in clinic, is indeed an interested area of study.  Furthermore, the in vivo activity 
of the bioactive glass will also be a very exciting area to explore; indeed, in a future study we will 
screen the activity of bioactive glass in cage fluids in a guinea-pig model. 
 
